Taking stock of the drug industry, from the lab to the medicine chest

March 11, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Justin Sullivan/Getty Images Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection A phase 3 trial is now planned for the new formulation of lenacapavir, which could advance once-yearly medicines for HIV and other diseases. By Jason Mast STAT+ | As GLP-1 compounding stares down a wall, telehealth companies pivot to hormones  No longer able to offer compounded versions of obesity drugs like Wegovy, many direct-to-consumer companies see hormone replacement as a new cash cow. By Katie Palmer Life sciences preprint servers have grown up — and are setting out on their own Sever will help lead a nonprofit created to ensure the future of the biomedical preprint servers bioRxiv and medRxiv, which he helped launch By Megan Molteni

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser